Fennec Pharmaceuticals Inc. (FENC)
Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Adherex Technologies Q2 Earnings Call Highlights
Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise.
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
Investors need to pay close attention to FENC stock based on the movements in the options market lately.
Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter
Fennec Pharmaceuticals NASDAQ: FENC executives outlined the company's commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference.
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Adherex Technologies Q1 Earnings Call Highlights
Adherex Technologies NASDAQ: FENC executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow and early signs that recent sales force investments are increasing demand.
Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.04 per share a year ago.
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.03. This compares to a loss of $0.06 per share a year ago.
Adherex Technologies Inc. (FENC) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Adherex Technologies (FENC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026
Fennec Pharmaceuticals is a commercial-stage oncology supportive-care company centered on Pedmark/Pedmarqsi. This drug helps reduce cisplatin-induced ototoxicity in pediatric patients who are battling cancer. Pedmark is FDA-approved for pediatric patients ≥1 month, and it has shown good efficacy so far with patients.
